Humanized mouse models in MDS.

Area of Science:

• Hematology
• Oncology
• Translational Medicine

Background:

• Myelodysplastic syndromes (MDS) are stem cell disorders characterized by ineffective blood cell production and a risk of progressing to acute myeloid leukemia.
• Current preclinical models struggle to fully replicate MDS pathophysiology due to a lack of human-specific support systems.

Purpose of the Study:

• To review current humanized and genetically engineered mouse models for studying MDS.
• To evaluate their effectiveness in replicating disease complexity, clonal evolution, and therapeutic responses.
• To identify limitations and propose future directions for improved preclinical models.

Main Methods:

• Review of existing literature on humanized mouse models (e.g., MISTRG, NSG-SGM3, NOG-EXL) for MDS.
• Analysis of models incorporating human cytokines, immunodeficient backgrounds, and co-transplantation strategies.
• Evaluation of model capacity for studying clonal evolution, disease dynamics, and treatment response.

Main Results:

• Humanized mouse models have enhanced engraftment and differentiation of human hematopoietic stem and progenitor cells.
• These models facilitate in vivo studies of clonal evolution, mutation-specific dynamics, and therapy response.
• Persistent challenges include limited long-term engraftment, incomplete immune reconstitution, and difficulty modeling early-stage MDS.

Conclusions:

• Humanized mouse models offer significant advancements for MDS research but require further development.
• Addressing limitations in engraftment, immune function, and early-stage disease modeling is crucial.
• New approaches are needed to enhance the standardization and clinical relevance of MDS preclinical models.